VKH
KPTI icon

Virtu KCG Holdings’s Karyopharm Therapeutics KPTI Stock Holding History

Virtu KCG Holdings’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,814
Closed -$265K – 3617
2016
Q3 		$265K Buy
+1,814
New +$218K 0.01% 2060
2014
Q3 		– Sell
-548
Closed -$383K – 3843
2014
Q2 		$383K Buy
+548
New +$255K 0.01% 2256

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Virtu KCG Holdings's KPTI Position: Q4 2016 in Review

Virtu KCG Holdings sold out of Karyopharm Therapeutics (KPTI) in Q4 2016, closing a stake of 1,814 shares — an estimated $265K sold.

Virtu KCG Holdings first reported a position in KPTI in Q2 2014 and held it in 2 quarters. The position peaked at $383K in Q2 2014. 86 funds tracked by Wall St. Rank hold KPTI as of Q4 2016.

  • Virtu KCG Holdings reported no remaining Karyopharm Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 1,814 Karyopharm Therapeutics shares in Q4 2016, an estimated $265K.
  • Virtu KCG Holdings first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 2 quarters.
  • Virtu KCG Holdings's Karyopharm Therapeutics position peaked at $383K in Q2 2014.
  • 86 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.